Idiopathic inflammatory myopathies

Seminars in Neurology

Volumn 32, Issue 3, 2012, Pages 227-236

  Dimachkie, Mazen M ^a   Barohn, Richard J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

dermatomyositis; myositis; necrotizing myopathy; polymyositis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ALOPECIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DEVICE THERAPY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; ELECTROPHYSIOLOGY; FEVER; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MUSCLE BIOPSY; MYOSITIS; NECROTIZING MYOPATHY; OCCUPATIONAL THERAPY; ORTHOTICS; PHYSIOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RASH; SKIN MANIFESTATION; TERATOGENICITY;

BIOLOGICAL MARKERS; DERMATOMYOSITIS; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; HUMANS; LUNG DISEASES, INTERSTITIAL; MYOSITIS; PHYSICAL THERAPY MODALITIES; POLYMYOSITIS; PROGNOSIS;

EID: 84868262366     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1329201     Document Type: Article

References (96)

1. Dimachkie M. M., Barohn R. J. Idiopathic inflammatory myopathies. Front Neurol Neurosci: 2009; 26 126 146
2. van der Meulen M. FG, Bronner I. M., Hoogendijk J. E., et al. Polymyositis: an overdiagnosed entity. Neurology: 2003; 61 3 316 321
3. Chahin N., Engel A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology: 2008; 70 6 418 424
4. Kuo C. F., See L. C., Yu K. H., et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol: 2011; 165 6 1273 1279
5. Quinter S. D., Chiu Y. E., Lyon V. B., Holland K. E., Ruggeri S. Y., Drolet B. A. Inverse Gottron's papules: an unusual cutaneous manifestation of juvenile dermatomyositis. Pediatr Dermatol: 2012; 29 5 641 644
6. Schmeling H., Stephens S., Goia C., et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford): 2011; 50 5 885 893
7. Shirani Z., Kucenic M. J., Carroll C. L., et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol: 2004; 29 3 273 276
8. Hundley J. L., Carroll C. L., Lang W., et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol: 2006; 54 2 217 220
9. Hoogendijk J. E., Amato A. A., Lecky B. R., et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord: 2004; 14 5 337 345
10. Bohan A., Peter J. B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med: 1975; 292 8 403 407
11. Amato A. A., Griggs R. C. Unicorns, dragons, polymyositis and other mythical beasts. Neurol (Tokyo): 2003; 61 288 289
12. Amato A. A., Barohn R. J. Idiopathic inflammatory myopathies. Neurol Clin: 1997; 15 3 615 648
13. Dalakas M. C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet: 2003; 362 9388 971 982
14. Pal S., Sanyal D. Jaw muscle weakness: a differential indicator of neuromuscular weakness-preliminary observations. Muscle Nerve: 2011; 43 6 807 811
15. Ellis E., Ann Tan J., Lester S., et al. Necrotizing myopathy: clinicoserologic associations. Muscle Nerve: 2012; 45 2 189 194
16. Suzuki S., Ohta M., Shimizu Y., Hayashi Y. K., Nishino I. Anti-signal recognition particle myopathy in the first decade of life. Pediatr Neurol: 2011; 45 2 114 116
17. Grable-Esposito P., Katzberg H. D., Greenberg S. A., Srinivasan J., Katz J., Amato A. A. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve: 2010; 41 2 185 190
18. Tymms K. E., Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol: 1985; 12 6 1140 1148
19. Marie I., Hatron P. Y., Dominique S., Cherin P., Mouthon L., Menard J. F. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum: 2011; 63 11 3439 3447
20. Hochberg M. C., Feldman D., Stevens M. B., Arnett F. C., Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol: 1984; 11 5 663 665
21. Targoff I. N., Miller F. W., Medsger T. A. Jr, Oddis C. V. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol: 1997; 9 6 527 535
22. Maoz C. R., Langevitz P., Livneh A., et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum: 1998; 27 5 319 324
23. Sigurgeirsson B., Lindelöf B., Edhag O., Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med: 1992; 326 6 363 367
24. Lakhanpal S., Bunch T. W., Ilstrup D. M., Melton L. J. III. Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc: 1986; 61 8 645 653
25. Scaling S. T., Kaufman R. H., Patten B. M. Dermatomyositis and female malignancy. Obstet Gynecol: 1979; 54 4 474 477
26. Rider L. G., Miller F. W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am: 1997; 23 3 619 655
27. Chen Y. J., Wu C. Y., Huang Y. L., Wang C. B., Shen J. L., Chang Y. T. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther: 2010; 12 2 R70
28. Miller T., Al-Lozi M. T., Lopate G., Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry: 2002; 73 4 420 428
29. Zöller B., Li X., Sundquist J., Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS ONE: 2012; 7 3 e33442
30. Eimer M. J., Brickman W. J., Seshadri R., et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr: 2011; 159 5 795 801
31. Titulaer M. J., Soffietti R., Dalmau J., et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol: 2011; 18 1 19 e3
32. Fathi M., Barbasso Helmers S., Lundberg I. E. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med: 2012; 271 6 589 597
33. Gono T., Kawaguchi Y., Sugiura T., et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford): 2010; 49 10 1878 1881
34. Ichimura Y., Matsushita T., Hamaguchi Y., et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis: 2012; 71 5 710 713
35. Joffe M. M., Love L. A., Leff R. L., et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med: 1993; 94 4 379 387
36. Suzuki S. [Anti-SRP myopathy]. Rinsho Shinkeigaku: 2011; 51 11 961 963
37. Kao A. H., Lacomis D., Lucas M., Fertig N., Oddis C. V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum: 2004; 50 1 209 215
38. Hanisch F., Müller T., Stoltenburg G., Zierz S. Unusual manifestations in two cases of necrotizing myopathy associated with SRP-antibodies. Clin Neurol Neurosurg: 2012; 114 7 1104 1106
39. Christopher-Stine L., Casciola-Rosen L. A., Hong G., Chung T., Corse A. M., Mammen A. L. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum: 2010; 62 9 2757 2766
40. Degardin A., Morillon D., Lacour A., Cotten A., Vermersch P., Stojkovic T. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol: 2010; 39 12 1219 1227
41. Kissel J. T., Mendell J. R., Rammohan K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med: 1986; 314 6 329 334
42. Emslie-Smith A. M., Engel A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol: 1990; 27 4 343 356
43. Pestronk A., Schmidt R. E., Choksi R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve: 2010; 42 1 53 61
44. De Visser M., Emslie-Smith A. M., Engel A. G. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci: 1989; 94 1-3 181 192
45. Greenberg S. A., Bradshaw E. M., Pinkus J. L., et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology: 2005; 65 11 1782 1787
46. Zhou X., Dimachkie M. M., Xiong M., Tan F. K., Arnett F. C. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med Sci Monit: 2004; 10 7 BR191 BR197
47. Walsh R. J., Kong S. W., Yao Y., et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum: 2007; 56 11 3784 3792
48. Liao A. P., Salajegheh M., Nazareno R., Kagan J. C., Jubin R. G., Greenberg S. A. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis: 2011; 70 5 831 836
49. Wong D., Kea B., Pesich R., et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS ONE: 2012; 7 1 e29161
50. Salaroli R., Baldin E., Papa V., et al. Validity of internal expression of the major histocompatibility complex class I in the diagnosis of inflammatory myopathies. J Clin Pathol: 2012; 65 1 14 19
51. Greenberg S. A., Pinkus G. S., Amato A. A., Pinkus J. L. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve: 2007; 35 1 17 23
52. Greenberg S. A., Pinkus J. L., Pinkus G. S., et al. Interferon-alpha/ beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol: 2005; 57 5 664 678
53. Greenberg S. A., Higgs B. W., Morehouse C., et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun: 2012; 13 3 207 213
54. Emslie-Smith A. M., Engel A. G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology: 1991; 41 6 936 939
55. Needham M., Fabian V., Knezevic W., Panegyres P., Zilko P., Mastaglia F. L. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord: 2007; 17 2 194 200
56. Niewold T. B., Wu S. C., Smith M., Morgan G. A., Pachman L. M. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics: 2011; 127 5 e1239 e1246
57. Bronner I. M., Hoogendijk J. E., Wintzen A. R., et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol: 2003; 250 4 480 485
58. Mammen A. L., Chung T., Christopher-Stine L., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum: 2011; 63 3 713 721
59. Mammen A. L., Pak K., Williams E. K., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken): 2012; 64 2 269 272
60. Amato A. A., Barohn R. J. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry: 2009; 80 11 1186 1193
61. Bunch T. W., Worthington J. W., Combs J. J., Ilstrup D. M., Engel A. G. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med: 1980; 92 3 365 369
62. Miller F. W., Leitman S. F., Cronin M. E., et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med: 1992; 326 21 1380 1384
63. Dalakas M. C., Illa I., Dambrosia J. M., et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med: 1993; 329 27 1993 2000
64. Miller J., Walsh Y., Saminaden S., Lecky B. RF, Winer J. B. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci: 2002; 199 01 S53
65. Vencovsk J., Jarosová K., Machácek S., et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol: 2000; 29 2 95 102
66. Villalba L., Hicks J. E., Adams E. M., et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum: 1998; 41 3 392 399
67. Muscle Study Group A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol: 2011; 70 3 427 436
68. Evans W. E., Hon Y. Y., Bomgaars L., et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol: 2001; 19 8 2293 2301
69. Booth R. A., Ansari M. T., Loit E., et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med: 2011; 154 12 814 823, W-295-W-298
70. Cherin P., Piette J. C., Wechsler B., et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol: 1994; 21 6 1092 1097
71. Danieli M. G., Malcangi G., Palmieri C., et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis: 2002; 61 1 37 41
72. Patwa H. S., Chaudhry V., Katzberg H., Rae-Grant A. D., So Y. T. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2012; 78 13 1009 1015
73. Rowin J., Amato A. A., Deisher N., Cursio J., Meriggioli M. N. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology: 2006; 66 8 1245 1247
74. Levine T. D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum: 2005; 52 2 601 607
75. Noss E. H., Hausner-Sypek D. L., Weinblatt M. E. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol: 2006; 33 5 1021 1026
76. Oddis C. V., Sciurba F. C., Elmagd K. A., Starzl T. E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet: 1999; 353 9166 1762 1763
77. Cagnoli M., Marchesoni A., Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol: 1991; 9 6 658 659
78. Oddis C. V., Reed A. M., Aggarwal R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - The RIM study. Arthritis Rheum: 2010; 62 3844
79. Valiyil R., Casciola-Rosen L., Hong G., Mammen A., Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken): 2010; 62 9 1328 1334
80. Park J. K., Yoo H. G., Ahn D. S., Jeon H. S., Yoo W. H. Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int: 2011;; Epub ahead of print
81. Brunasso A. M., Scocco G. L., Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol: 2010; 37 7 1549 1550
82. Mimori T., Nakashima R., Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep: 2012; 14 3 264 274
83. Morganroth P. A., Kreider M. E., Werth V. P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken): 2010; 62 10 1496 1501
84. Kotani T., Takeuchi T., Makino S., et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol: 2011; 30 8 1021 1028
85. Varjú C., Pethö E., Kutas R., Czirják L. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil: 2003; 17 1 83 87
86. Alexanderson H., Stenström C. H., Jenner G., Lundberg I. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol: 2000; 29 5 295 301
87. Alexanderson H. Exercise effects in patients with adult idiopathic inflammatory myopathies. Curr Opin Rheumatol: 2009; 21 2 158 163
88. Chung Y. L., Alexanderson H., Pipitone N., et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum: 2007; 57 4 694 702
89. Marie I., Hachulla E., Hatron P. Y., et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol: 2001; 28 10 2230 2237
90. Bronner I. M., van der Meulen M. F., de Visser M., et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis: 2006; 65 11 1456 1461
91. Limaye V., Hakendorf P., Woodman R. J., Blumbergs P., Roberts-Thomson P. Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J: 2012; 42 2 191 198
92. Airio A., Kautiainen H., Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol: 2006; 25 2 234 239
93. Marie I., Hatron P. Y., Levesque H., et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore): 1999; 78 3 139 147
94. Yamasaki Y., Yamada H., Ohkubo M., et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol: 2011; 38 8 1636 1643
95. Dankó K., Ponyi A., Constantin T., Borgulya G., Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore): 2004; 83 1 35 42
96. Benveniste O., Drouot L., Jouen F., et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum: 2011; 63 7 1961 1971